Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
07:15am, Monday, 03'rd Nov 2025
LAUSANNE, Switzerland , Nov. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
Ethic Inc. Purchases Shares of 37,862 ADC Therapeutics SA $ADCT
04:11am, Saturday, 01'st Nov 2025
Ethic Inc. acquired a new position in shares of ADC Therapeutics SA (NYSE: ADCT) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 37,862
ADC Therapeutics to Present at November Investor Conferences
07:15am, Monday, 27'th Oct 2025
LAUSANNE, Switzerland , Oct. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced pa
ADC Therapeutics Announces $60 Million Private Placement
07:30am, Monday, 13'th Oct 2025
LAUSANNE, Switzerland , Oct. 13, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Wednesday, 01'st Oct 2025
LAUSANNE, Switzerland , Oct. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Tuesday, 02'nd Sep 2025
LAUSANNE, Switzerland , Sept. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025
07:15am, Wednesday, 27'th Aug 2025
LAUSANNE, Switzerland , Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates
04:01pm, Tuesday, 12'th Aug 2025
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.38 per share a year ago.
ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Transcript
11:27am, Tuesday, 12'th Aug 2025
ADC Therapeutics SA (NYSE:ADCT ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Ameet Mallik - CEO & Director Jose I. Carmona - Chief Financial Officer Mohamed Zaki -
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
07:30am, Tuesday, 12'th Aug 2025
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients Expa
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
04:05pm, Tuesday, 05'th Aug 2025
LAUSANNE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
10:41am, Monday, 04'th Aug 2025
Here is how ADC Therapeutics SA (ADCT) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Friday, 01'st Aug 2025
LAUSANNE, Switzerland , Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan
04:05pm, Tuesday, 01'st Jul 2025
LAUSANNE, Switzerland , July 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69% CR maintained in 17 of 18 patients who achieved CR, wi
